SGLT2抑制剂治疗2型糖尿病的临床研究被引量：2

Clinical research of SGLT2 inhibitors for treating type 2 diabetes

导出

摘要钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是一种治疗2型糖尿病的新型药物，其通过特异性地抑制肾小管对葡萄糖的重吸收来降低血糖。目前，在欧美、日本等地已有大量的SGLT2抑制剂治疗2型糖尿病的临床试验，这些临床研究表明，SGLT2抑制剂在降低糖化血红蛋白、空腹血糖、体重等方面表现出更好的效果以及更少的不良反应。 Sodium-glucose co-transporters 2 （SGLT2） inhibitors is a new drug used for the treatment of type 2 diabetes, which can directly decrease blood glucose concentration by blocking reabsorption of filtered glucose in the renal tubule. Nowadays, many clinical studies of SGLT2 inhibitors with the type 2 diabetes were developed in the US, Europe and Japan. These researches showed that SGLT2 inhibitors performed better in reducing HbA1 c, fasting plasma glucose （FPG）, body weight and had less side effects.

作者刘宇翔李代清

机构地区天津医科大学内分泌研究所

出处《国际内分泌代谢杂志》 2016年第5期327-330,共4页 International Journal of Endocrinology and Metabolism

关键词 2型糖尿病 SGLT2抑制剂临床研究 Type 2 diabetes mellitus SGLT2 inhibitors Clinical treatment

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献25

1Yu L, Lv JC, Zhou X J, Abnormal expression and dysfunction of no- vel SGLT2 mutations identified in familial renal glueosuria patients [J]. Hum Genet,2011,129(3) :335-344. DOI: 10. 1007/s00439- 010-0927-z.
2Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in manage- ment of diabetes [ J ]. Lancet Diabetes Endocfinol, 2013,1 ( 2 ) : 140-151. DOI : 10. 1016/S2213-8587 ( 13)70050-0.
3Bode B, Stenlof K, Harris S,et al. Long-term efficacy and safety of eanagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes [ J ]. Diabetes Obes Metab, 2015,17 ( 3 ) : 294- 303. DOI: 10. 1111/dom. 12428.
4Nigro SC, Riche DM, Pheng M, et al. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes [ J ]. Ann Pharmacother, 2013, 47 ( 10 ) : 1301-1311. DOI: 10. 1177/ 1060028013503626.
5Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes : a random- ized, double-blind, placebo-controlled, 12-week study [ J ]. Diabetes Obes Metab, 2013, 15 (12): 1136-1145. DOI: 10. 1111/dom. 12149.
6Bell DS. The potent synergistic effects of the combination of lira- glutide and canagliflozin on glycemic control and weight loss[ J]. Am J Case Rep, 2014, 15: 152-154. DOI: 10. 12659/AJCR. 890626.
7Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glyeaemic con- trol with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial [ J]. Diabetes Obes Metab, 2011, 13 (10):928-938. DOI: 10.1111/j. 1463-1326. 2011. 01434. x.
8Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Jap- anese patients with inadequate glyeaemic control: a phase II mul- ticentre, randomized, double-blind, placebo-controlled trial[ J ]. Diabetes Obes Metab,2013,15 (5) :432-440. DOI: 10. 1111/ dora. 12047.
9Schumm-Draeger PM, Burgess L, Koranyi L,et al. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes : a 16-week randomized, placebo-controlled clinical trial [ J ]. Diabetes Obes Metab,2015,17 ( 1 ) :42-51. DOI: 10. 111l/ dom. 12387.
10Reilly TP, Graziano M J, Janovitz EB,et al. Careinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibi- tor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus [ J ]. Diabetes Ther, 2014,5 ( 1 ) : 73-96. DOI : 10.1007/s13300-01443053-3.